06 November 2009: Ossulin(TM) Shows Promising Bioavailability LONDON, 9th November 2009. New data from Puredel Limited, presented at the 9th Annual Diabetes Technology Meeting in San Francisco, California, suggest that higher blood levels of insulin were achieved by Ossulin than had been previously demonstrated by other products.  In a series of experiments in a range of doses and models, Ossulin consistently delivered around 20% of the insulin dose into the bloodstream. The authors concluded that: 'Ossulin provides an efficient way to deliver insulin to the body by oral administration, resulting in blood levels higher than those previously observed with other oral insulin products.' Lead author Dr Marco Prosdocimi added: 'Oral insulin could represent a major advance in diabetes therapy through its simplicity of use, and because it mimics the natural physiological route of the hormone.  The incorporation of insulin into the proprietary delivery agent Natsom (TM) gives rise to a product which is not destroyed by the gastric environment.' -ends- About Puredel Limited Puredel is focusing its research on the development of Ossulin, which has shown promising results in preliminary studies.  Puredel will also explore other target molecules which are currently injected and whose oral administration would greatly improve patient convenience and compliance.  Natreon's R&D staff and facilities in the United States and India are working closely with Puredel to help facilitate the next stage of scientific validation prior to commercial development. Puredel will coordinate the product development of Ossulin™ up to proof of clinical efficacy, drawing on its extensive network of scientific experts in Europe and North America. For further information please contact: Stephen Appelbee, CEO, CM&D Pharma Limited +44 20 7259 8488 appelbee@cmdpharmaltd.com www.cmdpharmaltd.com > Back